Dr. Juan Camilo Arjona Ferreira - 28 May 2021 Form 4 Insider Report for Myovant Sciences Ltd.

Role: Chief Medical Officer
Signature: /s/ Matthew Lang, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 28 May 2021
Net transactions value: -$63,878
Form type: 4
Filing time: 02 Jun 2021, 16:18:16 UTC
Previous filing: 28 May 2021
Next filing: 09 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MYOV	Common Shares	Options Exercise	$10,114	+1,300	+0.73%	$7.78	179,167	28 May 2021	Direct
transaction	MYOV	Common Shares	Sale	$31,200	-1,300	-0.73%	$24.00	177,867	28 May 2021	Direct	F1
transaction	MYOV	Common Shares	Sale	$42,792	-1,783	-1%	$24.00	176,084	28 May 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MYOV	Stock Option (Right to Buy)	Options Exercise	$0	-1,300	-0.69%	$0.000000	187,100	28 May 2021	Common Shares	1,300	$7.78	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold pursuant to a 10b5-1 trading plan.
F2	Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
F3	1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.